Anthropic (opens in new tab) said Wednesday, Sept. 23, that its Claude model helped flag a previously uncharacterized bacteriophage enzyme system the company named array-associated reverse transcriptases, or ART, according to the firm’s announcement and Reuters wire pickups.
Anthropic (opens in new tab) said ART pairs a reverse transcriptase with a neighboring accessory protein of unknown function and an array of non-coding DNA repeats whose layout resembles CRISPR arrays. The company said the reverse transcriptase itself had appeared in earlier literature, but that Claude’s agents appeared first to surface the broader system features while searching large DNA databases.
The firm said ART’s biological role is still unknown. Early laboratory work cited in the announcement indicates the repeat array is expressed as distinct short RNAs. Anthropic (opens in new tab) cast the finding as an early product of a new Bay Area wet lab and life-sciences research group and released a technical pre-print alongside the news.
The Event Log notes that Anthropic (opens in new tab)’s account does not establish ART as a ready gene-editing platform comparable to CRISPR; any therapeutic or editing use remains unproven and outside the confirmed record in today’s coverage.